Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Cash from Investing Activities (2020 - 2025)

Historic Cash from Investing Activities for Apellis Pharmaceuticals (APLS) over the last 6 years, with Q3 2025 value amounting to -$148000.0.

  • Apellis Pharmaceuticals' Cash from Investing Activities changed N/A to -$148000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$225000.0, marking a year-over-year increase of 4063.32%. This contributed to the annual value of -$403000.0 for FY2024, which is 4020.77% up from last year.
  • Per Apellis Pharmaceuticals' latest filing, its Cash from Investing Activities stood at -$148000.0 for Q3 2025.
  • Apellis Pharmaceuticals' Cash from Investing Activities' 5-year high stood at $179.6 million during Q3 2021, with a 5-year trough of -$271.9 million in Q1 2022.
  • For the 5-year period, Apellis Pharmaceuticals' Cash from Investing Activities averaged around $17.0 million, with its median value being -$33500.0 (2023).
  • In the last 5 years, Apellis Pharmaceuticals' Cash from Investing Activities soared by 9348461.54% in 2021 and then tumbled by 60000.0% in 2024.
  • Apellis Pharmaceuticals' Cash from Investing Activities (Quarter) stood at $85.0 million in 2021, then surged by 46.07% to $124.1 million in 2022, then plummeted by 100.0% to $4000.0 in 2023, then plummeted by 600.0% to -$20000.0 in 2024, then plummeted by 640.0% to -$148000.0 in 2025.
  • Its last three reported values are -$148000.0 in Q3 2025, -$49000.0 for Q2 2025, and -$8000.0 during Q1 2025.